Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | A promising treatment for prostate cancer

Michael Morris, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, explains how offering the combination of systemic and localized therapies early on the disease course can potentially improve the overall survival of high-risk prostate cancer patients. This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Transcript (edited for clarity)

What’s really also very interesting is if you looked at those three presentations yesterday showing that patients either with non-metastatic CRPC or with castration-sensitive disease that is metastatic, improving overall survival. There are multiple trials now that are ongoing in the rising PSA circumstance and also in a localized disease circumstance, in which those

What’s really also very interesting is if you looked at those three presentations yesterday showing that patients either with non-metastatic CRPC or with castration-sensitive disease that is metastatic, improving overall survival. There are multiple trials now that are ongoing in the rising PSA circumstance and also in a localized disease circumstance, in which those therapies are also being brought even earlier in the disease. And so there you really get into the very earliest phases of the disease where you have the potential, of course, if you can hit the right combination of active systemic therapies and local interventions potentially to significantly improve overall survival in patients, if not, get rid of their disease in patients for whom they would be otherwise at high risk of relapse and dying of disease.

Read more...